The dilated cardiomyopathy therapeutics market is set to reach US$ xx Mn by 2026 from US$ xx Mn in 2017, featuring magnificent growth at a compounded annual growth rate (CAGR) of 4.7% during the forecast period from 2018 to 2026. As per the latest research citations of the World Health Organization (WHO), annually, 17.9 million people die throughout the globe from cardiovascular diseases, which is equivalent to 31% of all global deaths. Factors responsible for congestive heart failure include a sedentary lifestyle, obesity, an unhealthy lifestyle, and congenital heart complications.
Pharmaceutical companies are striving earnestly to manufacture drugs with the fewest possible side effects and the desired therapeutic efficacy. Drugs in Phase III clinical trials showing promising results are enalapril orodispersible minitablets (Ethicare GmbH), ARRY-371797 (Array BioPharma), and ixCELL-DCM (Vericel Corporation).
Market Synopsis
Excellent clinical outcomes and satisfactory patient compliance make this drug class the most viable treatment option for dilated cardiomyopathy.
In the current scenario, drug classes are reigning in the treatment segment of the dilated cardiomyopathy therapeutics market. The parameters responsible for the growth of this drug class are the increasing number of patients diagnosed with congestive heart failure. Moreover, excellent clinical outcomes and satisfactory patient compliance make this drug class the most viable option for the treatment of dilated cardiomyopathy. Angiotensin-converting enzyme inhibitors (ACE inhibitors) are considered the first line of drug therapy due to their positive clinical effects, such as relaxing heart muscles and promoting blood flow. Angiotensin receptor blockers are given with diuretics to patients who do not tolerate ACE inhibitors. They help regulate the blood flow by widening blood vessels and reducing the fluid in the lungs and kidneys. Beta-blockers and anticoagulants are prescribed to reduce the pressure on the heart valves and prevent blood clotting in the heart chambers due to the inability of the weakened left ventricular muscles to pump blood. Implantable devices are gaining traction owing to the side effects associated with the drug class and the long-term benefit provided by devices such as heart pumps, biventricular pacemakers, and implantable cardioverter-defibrillators.
The increasing prevalence of congestive heart failure drives the growth of the dilated cardiomyopathy therapeutics market in North America.
North America is currently leading the geography segment for the dilated cardiomyopathy therapeutics market owing to factors such as the rising prevalence of congestive heart failure. According to the facts presented by the Centers for Disease Control and Prevention (CDC) in the United States, approximately 610,000 people die of heart disease annually. The existence of a well-developed healthcare infrastructure and an affordable reimbursement scenario drive the dilated cardiomyopathy market's growth in North America. As per the latest research citations of the European Heart Network (EHN), every year, 3.9 million people die in Europe, amounting to 45% of all deaths caused in the region. The domicile of major players such as Merck & Co., Inc., GlaxoSmithKline Plc, and t2cure GmbH, etc., propels market growth in the European Union region. Asia Pacific will register outstanding growth during the forecast period on account of the rising prevalence of congenital heart diseases, a favorable regulatory scenario, and growing medical tourism due to affordable treatment costs. Latin America, the Middle East, and Africa serve as potential markets to promote business expansion opportunities by establishing subsidiaries and retail outlets for major players providing treatment options for dilated cardiomyopathy.
Periods of History and Forecast
This research report presents the analysis of each segment from 2016 to 2026, considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2018 to 2026.
Report Scope by Segments
Market estimation and the compounded annual growth rate were determined by studying the latest market trends prevalent in the dilated cardiomyopathy therapeutics market. The market is divided into two sections: treatment and region.
Pharmaceutical companies spearheading the dilated cardiomyopathy therapeutics market are Aastrom Biosciences, Capricor Therapeutics, GlaxoSmithKline Plc, Johnson & Johnson, Kasiak Research Pvt. Ltd., Merck & Co., Inc., MyoKardia, Pfizer, Inc., t2cure GmbH, Teva Pharmaceutical Industries, and ZensunSci & Tech.
Key questions are answered in this report.
What are the organic and inorganic market growth strategies employed to determine the compounded annual growth rate and market estimation?
Which pharmaceutical and medical device companies are engaged to provide treatment options for dilated cardiomyopathy?
What are the DROs associated with the dilated cardiomyopathy therapeutics market?
What is the disease etiology of dilated cardiomyopathy and the treatment regimen adopted by physicians throughout the globe?
Which is the leading and fastest-growing treatment segment for the dilated cardiomyopathy therapeutics market?
Which is the leading and fastest-growing regional segment for the dilated cardiomyopathy therapeutics market?
Frequently Asked Questions:
The market for Dilated Cardiomyopathy Therapeutics is expected to reach US$ xx Mn in 2026.
The Dilated Cardiomyopathy Therapeutics market is expected to see significant CAGR growth over the coming years, at 4.7%.
The report is forecasted from 2018-2026.
The base year of this report is 2017.
Aastrom Biosciences,Capricor Therapeutics,GlaxoSmithKline plc.,Johnson and Johnson,Kasiak Research Pvt. Ltd. are some of the major players in the global market.
